BDR Pharma launches 80 mg version of prostate cancer drug at Rs 24,480 per pack in India

BDR Pharma launches 80 mg version of prostate cancer drug at Rs 24,480 per pack in India The company had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40 mg enzalutamide in 2017 to treat men with metastatic castration-resistant prostate cancer (mCRPC) under the brand name Bdenza, BDR Pharma said in a statement. https://ift.tt/eA8V8J